Drug Profile
Research programme: dendritic cell vaccines - Mendus
Alternative Names: IMM-2 platform; SUBCUVAX; SUBCUVAX®-AdenovirusLatest Information Update: 24 Jun 2022
Price :
$50
*
At a glance
- Originator Immunicum
- Developer Mendus
- Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 23 Jun 2022 Immunicum is now called Mendus
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in Sweden (SC, Injection)
- 29 Aug 2018 Preclinical development is still ongoing for Cancer in Sweden (Immunicum pipeline, August 2018)